> For the adjunctive use of laser photocoagulation and ranibizumab in DME and BRVO, see sections 4.2 and 5.1.   In clinical studies for the treatment of visual impairment due to DME, the outcome with regard to visual acuity or central RETINAL subfield thickness (CSFT) in patients treated with ranibizumab was not affected by concomitant treatment with THIAZOLIDINEDIONES. 
